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In this issue of Cell Stem Cell, Hooper et al. (2009) use a combination of immunohistochemistry and flow
cytometry to characterize the bonemarrow vasculature both before and after injury. The authors demonstrate
that recovery of normal hematopoiesis aftermyelosuppressive insult is dependent upon endothelial VEGFR2.The bonemarrowmicroenvironment plays
an important role in the regulationof hema-
topoietic stem cell (HSC) fate decisions
by influencing homing and survival and
determining the balance between self-
renewal and differentiation. Multiple cell
types in the bone marrow, such as osteo-
blasts, osteoclasts, endothelial cells, and
reticular cells, have been hypothesized
to function in the HSC niche. Although
much progress in the last several years
has been made in the ability to prospec-
tively identify and purify mouse HSCs,
the in vivo organization and cellular and
molecular mechanisms of HSC regulation
by the microenvironment are still only
beginning to be elucidated. A greater
understanding of the HSC niche would
provide opportunities for therapeutic
expansion ormanipulation of HSCs in clin-
ical settingsof hematopoieticdeficiencies.
Several independent studies have now
nicely demonstrated that osteoblasts
lining the trabecular bone surfaces within
the bone marrow cavity can modulate
the activity of HSCs, lending strong
support for the hypothesis that osteo-
blastic cells are an important component
of the HSCs niche (Porter and Calvi,
2008). However, other cell types likely
participate in the regulation of HSCs as
well, and several more recent studies
havepointed to thepossibilityof avascular
niche for HSCs. Previous data had already
supported important interactionsbetween
the bone marrow vascularity and hema-
topoietic progenitors, since endothelial
disruption resulted in impaired thrombo-
poiesis under physiologic and stress
conditions (Avecilla et al., 2004).
With regards to a role for endothelial
cells in HSC regulation, Kiel et al. firstdescribed the close association of HSCs
and sinusoidal endothelium cells (SECs)
using the SLAM receptors, CD150, CD48,
and CD41, as markers for HSCs in tissue
sections of mouse spleen and bone
marrow (Kiel et al., 2005). In this study,
the authors found approximately 60% of
bone marrow HSCs to be in close prox-
imity to SECs, whereas only 14% of
HSCs were adjacent to endosteal osteo-
blasts. In a separate study, again localiza-
tion of hematopoietic stem/progenitor
cells to specialized vascular structures
within the bone marrow microenviron-
ment was demonstrated, this time by
dynamic in vivo confocal imaging (Sipkins
et al., 2005). However, localization of well-
characterized HSCs does not necessarily
identify niche components, since a key
defining property of niche cells is their
ability to determine stem cell fate.
Expanding on the initial data identifying
colocalization of HSCs and vascular struc-
tures, Sugiyama et al. further character-
ized the proposed vascular niche by
describing a population of reticular cells
in the bone marrow that abundantly
express CXCL12, a chemokine known
to maintain the HSC pool in a quiescent
state, which they termed CAR cells
(Sugiyama et al., 2006). Since deletion of
CXCR4, the receptor for CXCL12, resulted
in a decrease in HSC quiescence and cell
numbers, along with increased sensitivity
to myelotoxic injury, CXCL12 is thought
to be critical in maintaining the HSC pool,
andCARcells appear tobe themostabun-
dant source of CXCL12 in the bone
marrow. Immunohistochemical analysis
of the bone marrow of CXCL12-GFP
knockin mice revealed that CAR cells are
scattered throughout the bone marrowCell Stem Cand that HSCs associated with both the
endosteum and the sinusoidal endothe-
lium are also in contact with CAR cells.
Further,a recentstudyusingacombination
of confocal microscopy and two-photon
video imaging to determine the spatial
fate of transplanted hematopoietic cells
demonstrated that osteoblasts are sur-
rounded by microvessels and concluded
that the endosteal niche is indeed perivas-
cular (Lo Celso et al., 2009). However,
these studies were performed in mouse
calvaria, and theproximityof theendosteal
osteoblasts to the vasculature in the long
bones remains to be determined. The
above studies lend support to the concept
of a vascular niche for HSCs; however,
the findings do not characterize in detail
the endothelial population, which may
be responsible for HSC support and/or
regulation.
Until now, convincing data demon-
strating that manipulation of the potential
vascular niche-affected HSC behavior
were lacking. In this issue of Cell Stem
Cell, Hooper et al. (2009) aim to more
precisely define the bonemarrowvascular
niche. Since it is technically difficult to do
quality imaging analyses on calcified
tissue, the bone marrow vasculature has
not been well characterized before this
study.Here, theauthorsuseacombination
of immunohistochemistryonbonemarrow
sections and polyvariate flow cytometry
on bone marrow cells to beautifully illus-
trate the morphology of the vasculature
within the bone marrow. These novel
methods allowed the authors to pheno-
typically distinguish bone marrow arteri-
oles from SECs using VEGFR3 and Sca1
expression and to nicely demonstrate
that SEC marker expression is uniqueell 4, March 6, 2009 ª2009 Elsevier Inc. 187
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hematopoietic cells. Notably, in the char-
acterization of these SECs, the authors
find that bone marrow SECs are localized
in close proximity to osteoblasts, and
point out that the endosteal and vascular
niches may not be distinct, as previously
proposed models suggested.
After characterizing these vessels in the
bonemarrow, Hooper et al. ask howSECs
are affected by myeloablative injury, and
use three different injury models that
caused regression of SECs to varying
degrees but did not deplete osteoblasts.
Characterization of damagedvessels after
injury demonstrates that discontinuous,
hemorrhagic vessels, labeled type I,
predominate after mild injury and in later
stages of recovery after moderate and
severe injury. More severely regressed
vessels with endothelial cells denuded
from the vessel walls, type II, are seen at
earlier time points after moderate/severe
injury. It was found that VEGFR2 and
VEGFR3 are differentially expressed
throughout the repair process, as are their
ligands, VEGF-A and VEGF-C, suggesting
that these signaling partners could be
playing a role in regenerating normal
SECs.
Todirectly show that regeneration of the
bone marrow vasculature after myeloa-
blative injury is dependent on VEGFR2,
Hooper et al. (2009) demonstrated that
treatment with neutralizing monoclonal
antibodies to VEFGR2 after moderate
injury or after severe injury with sub-
sequent bone marrow transplantation
prevents normal SEC regeneration and188 Cell Stem Cell 4, March 6, 2009 ª2009leads to hematopoietic deficits including
reduced bone marrow cellularity and
depletion of LSK and progenitor cells.
This finding suggests that VEGFR2 is
needed during bone marrow regeneration
after myelosuppression, not only for
proper assembly of SECs but also for
recovery of hematopoiesis. This depen-
dence on VEGFR2 for regeneration of the
vasculature and recovery of hematopoi-
esis after injury was also confirmed with
conditional deletion of the receptor. While
VEGFR2 is critical in the reestablishment
of normal vessels in the bone marrow
and the regeneration of hematopoiesis
after injury, similar experiments demon-
strated that VEGFR3 plays a more minor
role in this process, perhaps in remodeling
of newly formed vessels and ‘‘fine-tuning’’
of the hematopoietic system.
Thus, Hooper et al. (2009) have contrib-
uted very important additional data in
support of the existence of an endothelial
HSC niche by elegantly characterizing the
types of endothelial structures present
in the bone marrow and by identifying
specific endothelial-associated signals
(VEGFR2), which are required for hemato-
poietic recovery after myeloablation. The
identification of niche components is of
great interest not only biologically but
also as it has already been demonstrated
that HSCs can bemodified for therapeutic
gain by activating their microenvironment
(Adams et al., 2007; Arai et al., 2004; Calvi
et al., 2003). Data are still needed to deter-
mine whether activation of putative regu-
latory endothelial cells within the bone
marrow microenvironment is sufficient toElsevier Inc.expand HSCs. However, the greater
understanding of the characteristics of
these cells provided by the current work
byHooper et al. is likely to greatly facilitate
such studies, which could provide further
targets for HSC expansion through
manipulation of their niche.
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